Bressan, R. A., Jones, H. M., & Pilowsky, L. S. (2004). Atypical antipsychotic drugs and tardive dyskinesia: Relevance of D2 receptor affinity. Journal of Psychopharmacology, 18(1), 124–127. https://doi.org/10.1177/0269881104040251

Güzey, C., Scordo, M. G., Spina, E., et al. (2007). Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: Associations with dopamine and serotonin receptor and transporter polymorphisms. European Journal of Clinical Pharmacology, 63(3), 233–241. https://doi.org/10.1007/s00228-006-0234-8

Olasore, H. S. A., Oyedeji, T. A., Faleti, J. O., Ogundele, O. I., & Olashore, A. A. (2024). Association between dopamine receptor D2 Taq IA gene polymorphism (rs1800497) and personality traits. SAGE Open Medicine, 12, 20503121241241922. https://doi.org/10.1177/20503121241241922
SpringerLink

Ohio State University, Columbus

The DRD2 gene encodes the dopamine D2 receptor which is the main target for many antipsychotic medications.

A1 Allele Carriers (A1/A1 variant): Individuals with the A1 allele have reduced D2 receptor density in brain regions such as the striatum, which can lead to heightened sensitivity to the antagonistic effects caused by Antipsychotics on the D2 receptor. As a result, these individuals are more likely to experience extrapyramidal symptoms (EPS) such as tremors, rigidity, and akathisia, even at low doses. Overall, those who carry the A1 allele of the DRD2 gene may require dose adjustments or other therapies to avoid these side effects as EPS such as TD which can be permanent.

Learn Before

Related